Discover
01Performance is
our duty
As a preclinical oncology CRO, XenTech believe in expertise, carry innovative values and creative solutions to facilitate and make emerge new efficient tools to fight cancer globally. We’re not in the size or numbers’ race but rather favor precisely targeted tools and services that will provide easier and faster solutions to the oncology research community and ultimately improve patients’ health.
With this spirit we are constantly evolving and prefer focusing on underserved niche (pediatric oncology), accurate models addressing nowadays needs in oncology research (MATCH-R line of PDX reflecting acquired resistance to newly approved or in clinical evaluation drugs) and capitalize on our historic expertise in Breast cancer for which we aim to be THE #1 Reference.
Discover
01They trust us
01Our latest
publications
01.24.23
XenTech will attend the DDR inhibitors Summit 2023 (Boston, Jan. 24-26)
Our Head of R&D Oliver Déas will be delighted to discuss with you as he'll be attending in person.
Discover
06.20.22
XenTech exhibits at EACR 2022 (Seville, Jun. 20-23 2022)
We'll be exhibiting at EACR in Seville, stop by booth #50 !
Discover
04.15.22
Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification
Discover
05.05.22
Targeting genome integrity dysfunctions impedes metastatic potency in non-small-cell lung cancer circulating tumor cellderived eXplants
CTC-derived eXplants (CDX) offer systems for mechanistic investigation of CTC metastatic potency and may provide rationale for biology-driven therapeutics.
Discover
